Oaktree Acquisition Corp. III Life Sciences (OACC) · Oct 26, 2026 · Other events
Deadline extended — November 25, 2026, with extensions possible through May 25, 2027
Oaktree Acquisition Corp. III Life Sciences wins more time for a business combination, but heavy redemptions shrink its public capital base.
Oaktree Acquisition Corp. III Life Sciences remains a blank-check company searching for an initial life-sciences business combination, rather than an operating company with its own commercial business. The extension proposal and its basic terms were already publicly disclosed before the vote, so the approval itself is mostly confirmation rather than a fresh strategic development.
The SPAC bought additional time, but not a transaction. Shareholders approved moving the termination date from October 25, 2026 to November 25, 2026, with authority for monthly extensions through May 25, 2027. The filing says the Articles Amendment was filed with the Cayman Islands Registrar, making the extension effective.
The important offset is the scale of shareholder withdrawals. Holders redeemed 11,331,102 public shares for approximately $122.4 million, at roughly $10.805 per share. That materially reduces the public capital available for a future transaction; the filing does not provide a post-redemption cash balance, so the remaining funding base cannot be quantified from this report.
The sponsor converted founder shares into Class A shares, but this is not new financing. OAC issued 4,798,758 Class A shares to the sponsor in exchange for the same number of Class B shares, leaving the sponsor with 5,382,739 Class A shares and 1,000 Class B shares. The conversion preserves the sponsor’s voting and deal-support position, but the filing describes no cash contribution alongside it.
Approval was decisive, not marginal. The proposal received 17,956,072 votes for and 802,517 against, with a 76.3% quorum; the adjournment proposal was therefore not needed. 〔0〕
| Filing item | Result |
|---|---|
| New initial deadline | November 25, 2026 (Articles Amendment) |
| Maximum possible deadline | May 25, 2027 (Articles Amendment) |
| Public shares redeemed | 11,331,102 (Shareholder vote / redemptions) |
| Redemption amount | Approximately $122,435,287 (Shareholder vote / redemptions) |
| Sponsor shares converted | 4,798,758 Class B to Class A (Item 3.02) |
| Vote for / against | 17,956,072 / 802,517 (Item 5.07) |
Bottom line: The filing keeps the SPAC alive for several more months, but it does not show progress toward a signed target and confirms a substantial reduction in public capital. The extension is operationally necessary, while the redemptions make the eventual transaction harder to fund.
Business combination by November 25, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!